![JCM | Free Full-Text | Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience JCM | Free Full-Text | Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience](https://pub.mdpi-res.com/jcm/jcm-12-02429/article_deploy/html/images/jcm-12-02429-g001-550.jpg?1679458971)
JCM | Free Full-Text | Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience
![JCM | Free Full-Text | Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience JCM | Free Full-Text | Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience](https://www.mdpi.com/jcm/jcm-12-02429/article_deploy/html/images/jcm-12-02429-g001.png)
JCM | Free Full-Text | Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience
![Frontiers | Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders Frontiers | Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders](https://www.frontiersin.org/files/Articles/1090548/fimmu-14-1090548-HTML/image_m/fimmu-14-1090548-g001.jpg)
Frontiers | Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders
![JCM | Free Full-Text | Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience JCM | Free Full-Text | Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience](https://www.mdpi.com/jcm/jcm-12-02429/article_deploy/html/images/jcm-12-02429-g002-550.jpg)